Cargando…
Neurofibromatosis Type 1–Associated MPNST State of the Science: Outlining a Research Agenda for the Future
Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma for which the only effective therapy is surgery. In 2016, an international meeting entitled “MPNST State of the Science: Outlining a Research Agenda for the Future” was convened to establish short- and long-term res...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057517/ https://www.ncbi.nlm.nih.gov/pubmed/29117388 http://dx.doi.org/10.1093/jnci/djx124 |
_version_ | 1783341540023730176 |
---|---|
author | Reilly, Karlyne M. Kim, AeRang Blakely, Jaishri Ferner, Rosalie E. Gutmann, David H. Legius, Eric Miettinen, Markku M. Randall, R. Lor Ratner, Nancy Jumbé, N. L. Bakker, Annette Viskochil, David Widemann, Brigitte C. Stewart, Douglas R. |
author_facet | Reilly, Karlyne M. Kim, AeRang Blakely, Jaishri Ferner, Rosalie E. Gutmann, David H. Legius, Eric Miettinen, Markku M. Randall, R. Lor Ratner, Nancy Jumbé, N. L. Bakker, Annette Viskochil, David Widemann, Brigitte C. Stewart, Douglas R. |
author_sort | Reilly, Karlyne M. |
collection | PubMed |
description | Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma for which the only effective therapy is surgery. In 2016, an international meeting entitled “MPNST State of the Science: Outlining a Research Agenda for the Future” was convened to establish short- and long-term research priorities. Key recommendations included the: 1) development of standardized, cost-efficient fluorodeoxyglucose positron emission tomography and whole-body magnetic resonance imaging guidelines to evaluate masses concerning for MPNST; 2) development of better understanding and histologic criteria for the transformation of a plexiform neurofibroma to MPNST; 3) establishment of a centralized database to collect genetic, genomic, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from MPNST subspecialty centers in a standardized manner; 4) creation of accurate mouse models to study the plexiform neurofibroma-to-MPNST transition, MPNST metastasis, and drug resistance; 5) use of trial designs that minimize regulatory requirements, maximize availability to patients, consider novel secondary end points, and study patients with newly diagnosed disease. Lastly, in order to minimize delays in developing novel therapies and promote the most efficient use of research resources and patient samples, data sharing should be incentivized. |
format | Online Article Text |
id | pubmed-6057517 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-60575172018-07-27 Neurofibromatosis Type 1–Associated MPNST State of the Science: Outlining a Research Agenda for the Future Reilly, Karlyne M. Kim, AeRang Blakely, Jaishri Ferner, Rosalie E. Gutmann, David H. Legius, Eric Miettinen, Markku M. Randall, R. Lor Ratner, Nancy Jumbé, N. L. Bakker, Annette Viskochil, David Widemann, Brigitte C. Stewart, Douglas R. J Natl Cancer Inst Commentary Malignant peripheral nerve sheath tumor (MPNST) is an aggressive soft tissue sarcoma for which the only effective therapy is surgery. In 2016, an international meeting entitled “MPNST State of the Science: Outlining a Research Agenda for the Future” was convened to establish short- and long-term research priorities. Key recommendations included the: 1) development of standardized, cost-efficient fluorodeoxyglucose positron emission tomography and whole-body magnetic resonance imaging guidelines to evaluate masses concerning for MPNST; 2) development of better understanding and histologic criteria for the transformation of a plexiform neurofibroma to MPNST; 3) establishment of a centralized database to collect genetic, genomic, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from MPNST subspecialty centers in a standardized manner; 4) creation of accurate mouse models to study the plexiform neurofibroma-to-MPNST transition, MPNST metastasis, and drug resistance; 5) use of trial designs that minimize regulatory requirements, maximize availability to patients, consider novel secondary end points, and study patients with newly diagnosed disease. Lastly, in order to minimize delays in developing novel therapies and promote the most efficient use of research resources and patient samples, data sharing should be incentivized. Oxford University Press 2017-08-22 /pmc/articles/PMC6057517/ /pubmed/29117388 http://dx.doi.org/10.1093/jnci/djx124 Text en © The Author 2017. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Commentary Reilly, Karlyne M. Kim, AeRang Blakely, Jaishri Ferner, Rosalie E. Gutmann, David H. Legius, Eric Miettinen, Markku M. Randall, R. Lor Ratner, Nancy Jumbé, N. L. Bakker, Annette Viskochil, David Widemann, Brigitte C. Stewart, Douglas R. Neurofibromatosis Type 1–Associated MPNST State of the Science: Outlining a Research Agenda for the Future |
title | Neurofibromatosis Type 1–Associated MPNST State of the Science: Outlining a Research Agenda for the Future |
title_full | Neurofibromatosis Type 1–Associated MPNST State of the Science: Outlining a Research Agenda for the Future |
title_fullStr | Neurofibromatosis Type 1–Associated MPNST State of the Science: Outlining a Research Agenda for the Future |
title_full_unstemmed | Neurofibromatosis Type 1–Associated MPNST State of the Science: Outlining a Research Agenda for the Future |
title_short | Neurofibromatosis Type 1–Associated MPNST State of the Science: Outlining a Research Agenda for the Future |
title_sort | neurofibromatosis type 1–associated mpnst state of the science: outlining a research agenda for the future |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057517/ https://www.ncbi.nlm.nih.gov/pubmed/29117388 http://dx.doi.org/10.1093/jnci/djx124 |
work_keys_str_mv | AT reillykarlynem neurofibromatosistype1associatedmpnststateofthescienceoutliningaresearchagendaforthefuture AT kimaerang neurofibromatosistype1associatedmpnststateofthescienceoutliningaresearchagendaforthefuture AT blakelyjaishri neurofibromatosistype1associatedmpnststateofthescienceoutliningaresearchagendaforthefuture AT fernerrosaliee neurofibromatosistype1associatedmpnststateofthescienceoutliningaresearchagendaforthefuture AT gutmanndavidh neurofibromatosistype1associatedmpnststateofthescienceoutliningaresearchagendaforthefuture AT legiuseric neurofibromatosistype1associatedmpnststateofthescienceoutliningaresearchagendaforthefuture AT miettinenmarkkum neurofibromatosistype1associatedmpnststateofthescienceoutliningaresearchagendaforthefuture AT randallrlor neurofibromatosistype1associatedmpnststateofthescienceoutliningaresearchagendaforthefuture AT ratnernancy neurofibromatosistype1associatedmpnststateofthescienceoutliningaresearchagendaforthefuture AT jumbenl neurofibromatosistype1associatedmpnststateofthescienceoutliningaresearchagendaforthefuture AT bakkerannette neurofibromatosistype1associatedmpnststateofthescienceoutliningaresearchagendaforthefuture AT viskochildavid neurofibromatosistype1associatedmpnststateofthescienceoutliningaresearchagendaforthefuture AT widemannbrigittec neurofibromatosistype1associatedmpnststateofthescienceoutliningaresearchagendaforthefuture AT stewartdouglasr neurofibromatosistype1associatedmpnststateofthescienceoutliningaresearchagendaforthefuture |